News & Updates
Showing Pharmacy articles
Showing
Show Multimedia Only

OASIS-1: Thumbs up for mirikizumab in moderate-to-severe plaque psoriasis
23 Aug 2022
byJairia Dela Cruz
The interleukin (IL)-23 inhibitor mirikizumab demonstrates superior efficacy in the treatment of patients with moderate-to-severe plaque psoriasis as compared with placebo, with initial responses during induction preserved through the maintenance phase, according to the results of the phase III OASIS-1 trial.
23 Aug 2022

FLT3 inhibitor improves survival in patients with FLT3+ acute myeloid leukaemia
23 Aug 2022
Patients diagnosed with acute myeloid leukaemia with an FLT3 mutation (FLT3+ AML) may benefit from the addition of an FLT3 inhibitor to intensive chemotherapy postinduction by improving event-free (EFS) or overall survival (OS), suggests a study.
23 Aug 2022







